Mechanism of Oxidation of 1-Methyl-4-Phenyl-3,3-Dihydropyridinium (MPDP+)
The compound 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin found as a contaminant in certain street drugs. Individuals using these drugs can develop symptoms similar to those of Parkinson’s disease.1–3 The symptoms have been attributed to MPTP, which is known to produce Parkinsonian symptoms in some animals4,5 and which selectively destroys neuronal cells in the melanin-containing substantia nigra of humans and primates. The conversion of MPTP to reactive metabolites by monoamine oxidase in brain tissue is crucial for MPTP neurotoxicity.6–7 Production of oxygen radicals from metabolites of MPTP has been proposed to account for its selective neuronal damage.8–13
KeywordsSubstantia Nigra Tertiary Amine Reactive Metabolite Parkinsonian Symptom Selective Destruction
Unable to display preview. Download preview PDF.
- 3.J. M. Wright, R. A. Wall, T. L. Perry, and D. W. Paty, Chronic Parkinsonsim secondary to intranasol administration of a product of meperidine-analog synthesis, N. Eng. J. Med. 310:325 (1984).Google Scholar
- 4.R. S. Burns, C. C. Chiueh, S. P. Markey, M. H. E. Ebert, D. Jacobowitz, and I. J. Kopin, A primate model of Parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Proc. Natl. Acad. Sci. USA 80:4546 (1984).CrossRefGoogle Scholar
- 10.V. W. Young, T. L. Perry, and A. A. Krisman, Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pre-treatment, Neurosci. Lett. 63:56 (1986).Google Scholar